
Advances in **CANCER RESEARCH**

Volume 75

Edited by

George F. Vande Woude

*ABL-Basic Research Program
National Cancer Institute
Frederick Cancer Research and Development Center
Frederick, Maryland*

George Klein

*Microbiology and Tumor Biology Center
Karolinska Institutet
Stockholm, Sweden*



ACADEMIC PRESS

San Diego London Boston
New York Sydney Tokyo Toronto

Contributors to Volume 75 ix

Specificity within the *ets* Family of Transcription Factors

Barbara J. Graves and Jeannine M. Petersen

- I. Introduction 2
- II. Sequence Conservation 3
- III. Biological Specificity 13
- IV. DNA Binding 21
- V. Protein Partnerships 29
- VI. Transcriptional Activation and Repression 35
- VII. Signal Transduction 38
- VIII. Autoinhibition 42
- IX. Perspectives: *ets* Proteins and Cancer 47
- References 49

Kaposi's Sarcoma-Associated Herpesvirus

C. Boshoff and R. A. Weiss

- I. Introduction 58
- II. New Herpesvirus: KSHV/HHV-8 62
- III. KSHV and Lymphoproliferation 68
- IV. Viral Piracy of Eukaryotic Genes 70
- V. Anti-"Antiviral" Responses 72
- VI. Role of KSHV in KS Pathogenesis: Direct or Indirect? 78
- VII. Therapeutic Implications 79
- References 80

Extracellular Matrix-Associated Transforming Growth Factor- β : Role in Cancer Cell Growth and Invasion

Jussi Taipale, Juha Saharinen, and Jorma Keski-Oja

- I. Introduction 88
- II. Structure of TGF- β s 89

III. Expression of TGF- β s and Latent TGF- β Binding Proteins	93
IV. Mechanisms of Activation of Latent TGF- β	96
V. Signal Transduction by TGF- β	100
VI. Control of Gene Expression by TGF- β	104
VII. Biological Effects of TGF- β	105
VIII. TGF- β in Oncogenesis	112
IX. Perspective	120
References	120

Differentiation and Cancer in the Mammary Gland: Shedding Light on an Old Dichotomy

Ole W. Petersen, Lone Rønnev-Jessen, Valerie M. Weaver, and Mina J. Bissell

I. Introduction	136
II. Markers of Breast Differentiation	138
III. Culture Models of Mammary Gland Differentiation	146
IV. Conclusion	156
References	157

Inherited Carcinomas of the Kidney

Berton Zbar and Michael Lerman

I. Introduction	164
II. Inherited Carcinomas of the Kidney: Histology	164
III. Inherited Carcinomas of the Kidney: Clinical Syndromes	166
IV. Papillary Renal Carcinoma: Pathology and Genetics	169
V. Clear Cell Renal Carcinomas: Pathology and Genetics	179
VI. Other Renal Carcinomas	184
VII. Genes That Predispose to Carcinomas of the Kidney	187
VIII. Recognition of Families with Inherited Kidney Cancer	192
IX. Toward a Genetic Classification of Renal Tumors	192
X. Conclusions	193
References	194

The Labyrinthine Ways of Cancer Immunotherapy—T Cell, Tumor Cell Encounter: “How Do I Lose Thee? Let Me Count the Ways”

K. A. O. Ellem, C. W. Schmidt, C.-L. Li, I. Misko, A. Kelso, G. Sing,
G. Macdonald, and M. G. E. O'Rourke

I. Introduction	204
II. Cancer as a Moving Target	205
III. Genomic Instability and the Mutator Phenotype	207
IV. Induction of an Antitumor Immune Response Is Not the Major Problem	211
V. Immune Basis for the “Second-Order Bystander Effect”	212

- VI. The Vanishing Target 214
- VII. Defeat of the NK Cell Default 217
- VIII. T Lymphocyte Inadequacies 220
- IX. Stromal Shielding? 222
- X. The trCTLp 223
- XI. Opportunistic Expression of the FasL Weapon by Tumor Cells 227
- XII. T Cells as Officers Rather Than Troops 228
- XIII. Tumor Rejection Is a Combined Action 231
- XIV. The Blood-Tumor Barrier 231
- XV. CODA-1: Proposed Solutions 235
- XVI. Some Obvious Stratagems 237
- XVII. CODA-2: Sample Flow Chart of an Arborizing Clinical Trial 241
- References 242

CD95(APO-1/Fas)-Mediated Apoptosis in Normal and Malignant Liver, Colon, and Hematopoietic Cells

Peter H. Krammer, Peter R. Galle, Peter Möller, and Klaus-Michael Debatin

- I. The CD95 System 252
- II. CD95 in Liver Disease 256
- III. CD95 in the Colon 258
- IV. CD95 and Hematopoietic Malignancies 264
- V. Conclusions 269
- References 269

Index 275